This Plain Language Summary of Publication article (PLSP) from Future Oncology, highlights the 7-year results from part 1 of the COLUMBUS study, which evaluated the effectiveness of combining encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) compared to encorafenib or vemurafenib (ZELBORAF®) alone for treating locally advanced or metastatic BRAF V600-mutant melanoma.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma’ and was published in the European Journal of Cancer.

Visit EJC using the link to read the original article.